Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.63 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.63 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 9/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | MITF | O75030 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27664452 | 0.89 | ADRA2A (0.79) | ADRA2AADRA2BADRA2CMAPTALDH1A1 | |
| Nitric Acid SCHEMBL6991286 | 0.84 | ADRA2C (0.66) | ADRA2AADRA2BADRA2CMAPTALDH1A1 | |
| Nitric Acid SCHEMBL1363345 | 0.75 | MAPT (0.57) | MAPTALDH1A1SMN1; SMN2KDM4EPKM | |
| SCHEMBL9424014 | 0.73 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CMAPTALDH1A1 | |
| Nitric Acid SCHEMBL6033862 | 0.72 | CA12 (0.72) | ADRA2AADRA2BADRA2CPLAUPOLB | |
| SCHEMBL3975045 | 0.71 | ADRA2C (0.82) | ADRA2AADRA2BADRA2CMAPTALDH1A1 | |
| SCHEMBL85548 | 0.71 | AKR1C3 (0.71) | MAPTALDH1A1SMN1; SMN2KDM4EPKM | |
| Nitric Acid SCHEMBL1833741 | 0.71 | PLAU (0.73) | ADRA2AADRA2BADRA2CPLAUPOLB | |
| Nitric Acid SCHEMBL2544085 | 0.71 | PLAU (0.73) | ADRA2AADRA2BADRA2CPLAUPOLB | |
| SCHEMBL12247909 | 0.71 | AKR1C3 (0.54) | MAPTALDH1A1SMN1; SMN2KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222682-A1 | IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Abbott Laboratories (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009070516-A1 | IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-06-04 | — | — | WO | disclosed |
| EP-1187816-B1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | CELLTECH R&D LTD (GB) | 2006-12-20 | — | — | EP | disclosed |
| US-20040180914-A1 | 5-Cyano-2-aminopyrimidine derivatives | CELLTECH R&D LIMTIED | 2004-09-16 | — | — | US | disclosed |
| US-6579983-B1 | Potent and selective inhibitors of receptor tyrosine kinases involved in angiogenesis, especially KDR kinase and/or FGFr kinase | CELLTECH R&D LIMITED (GB) | 2003-06-17 | — | — | US | disclosed |
| US-20020147339-A1 | 5-cyano-2-aminopyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2002-10-10 | — | — | US | disclosed |
| EP-1187816-A1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | Celltech R&D Limited (GB) | 2002-03-20 | — | — | EP | disclosed |
| WO-2000078731-A1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | CELLTECH R&D LIMITED (GB) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180914-A1 | 5-Cyano-2-aminopyrimidine derivatives | FLT1, FGFR1, KDR | ADRA2A 794/4885ADRA2B 386/4885ADRA2C 543/4885 |
| US-20020147339-A1 | 5-cyano-2-aminopyrimidine derivatives | FLT1, FGFR1, KDR | ADRA2A 680/4885ADRA2B 337/4885ADRA2C 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.